MedTrace Logo

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

NCT02764801 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2025-05-06

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic resonance (MRI) or computed tomography (CT) imaging

Conditions

Interventions

DRUG

Ultrasound contrast agent (Contrast-enhanced ultrasound)

Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.

DEVICE

Logiq E9 Scanner (Contrast-enhanced ultrasound)

Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.

Sponsors & Collaborators

  • University of California, San Diego

    collaborator OTHER

  • Vanderbilt University Medical Center

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • Lantheus Medical Imaging

    collaborator INDUSTRY

  • GE Healthcare

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • John Eisenbrey, PhD · Thomas Jefferson University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2021-12-31
Completion
2023-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02764801 on ClinicalTrials.gov